Skip to main content

Palmitoyl Tripeptide-1 vs Pinealon

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Palmitoyl Tripeptide-1

Palmitoyl Tripeptide-1 (Pal-GHK) is a lipopeptide that stimulates collagen production. It's one of two peptides in the Matrixyl 3000 complex, working synergistically with Palmitoyl Tetrapeptide-7.

Full details →

Pinealon

Pinealon is a short synthetic peptide developed from research on the pineal gland. It has shown neuroprotective and cognitive-enhancing properties in animal studies.

Full details →

Side-by-Side Comparison

AspectPalmitoyl Tripeptide-1Pinealon
MechanismMimics the skin's own mechanism for producing collagen by acting as a messenger peptide that signals fibroblasts to produce more collagen and other extracellular matrix components.Penetrates cell membranes and interacts with DNA to regulate gene expression related to neuronal survival and function. May support pineal gland function and melatonin production.
Typical DosageTopical: Typically 2-4% in serums, often combined with Palmitoyl Tetrapeptide-7 as Matrixyl 3000.Typical dosing: 10-20mg daily, taken in divided doses. Often used in cycles of 10-20 days.
AdministrationTopical application 1-2 times daily. The palmitoyl group enhances skin penetration compared to non-lipidated versions.Can be taken orally (capsules) or sublingually. Best absorbed on an empty stomach. Often combined with other neuroprotective peptides.
Side EffectsVery well-tolerated. Suitable for most skin types including sensitive skin.Generally well-tolerated. Limited reported side effects. May affect sleep patterns initially.
Best For

Key Differences

Detailed Analysis

Commonalities

Palmitoyl Tripeptide-1 and Pinealon are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose Palmitoyl Tripeptide-1 for Anti-Aging & Longevity, Skin Health & Aesthetics. Choose Pinealon for Sleep Quality, Cognitive Performance.

Ready to Learn More?